Literature DB >> 12807996

Cilostazol prevents tumor necrosis factor-alpha-induced cell death by suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and activation of Akt/cyclic AMP response element-binding protein phosphorylation.

Ki Whan Hong1, Ki Young Kim, Hwa Kyoung Shin, Jeong Hyun Lee, Jae Moon Choi, Yong-Geun Kwak, Chi Dae Kim, Won Suk Lee, Byung Yong Rhim.   

Abstract

This study examines the signaling mechanism by which cilostazol prevents neuronal cell death. Cilostazol ( approximately 0.1-100 microM) prevented tumor necrosis factor-alpha (TNF-alpha)-induced decrease in viability of SK-N-SH and HCN-1A cells, which was antagonized by 1 microM iberiotoxin, a maxi-K channel blocker. TNF-alpha did not suppress the viability of the U87-MG cell, a phosphatase and tensin homolog deleted from chromosome 10 (PTEN)-null glioblastoma cell, but it did decrease viability of U87-MG cells transfected with expression vectors for the sense PTEN, and this decrease was also prevented by cilostazol. Cilostazol as well as 1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one (NS-1619) and (3S)(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indole-2-one (BMS 204352), maxi-K channel openers, prevented increased DNA fragmentation evoked by TNF-alpha, which were antagonizable by iberiotoxin. TNF-alpha-induced increased PTEN phosphorylation and decreased Akt/cyclic AMP response element-binding protein (CREB) phosphorylation were significantly prevented by cilostazol, those of which were antagonized by both iberiotoxin and paxilline, maxi-K channel blockers. The same results were evident in U87-MG cells transfected with expression vectors for sense PTEN. Cilostazol increases the K+ current in SK-N-SH cells by activating maxi-K channels without affecting the ATP-sensitive K+ channel. Thus, our results for the first time provide evidence that cilostazol prevents TNF-alpha-induced cell death by suppression of PTEN phosphorylation and activation of Akt/CREB phosphorylation via mediation of the maxi-K channel opening.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12807996     DOI: 10.1124/jpet.103.052365

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  HO-1 Induced by Cilostazol Protects Against TNF-α-associated Cytotoxicity via a PPAR-γ-dependent Pathway in Human Endothelial Cells.

Authors:  So Youn Park; Jin Ung Bae; Ki Whan Hong; Chi Dae Kim
Journal:  Korean J Physiol Pharmacol       Date:  2011-04-30       Impact factor: 2.016

2.  Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells.

Authors:  So Youn Park; Jeong Hyun Lee; Hwa Kyoung Shin; Chi Dae Kim; Won Suk Lee; Byung Yong Rhim; Yung Woo Shin; Ki Whan Hong
Journal:  Korean J Physiol Pharmacol       Date:  2008-08-31       Impact factor: 2.016

Review 3.  Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.

Authors:  Jeong Hyun Lee; So Youn Park; Hwa Kyoung Shin; Chi Dae Kim; Won Suk Lee; Ki Whan Hong
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

4.  Cilostazol disrupts TLR-4, Akt/GSK-3β/CREB, and IL-6/JAK-2/STAT-3/SOCS-3 crosstalk in a rat model of Huntington's disease.

Authors:  Hanan El-Abhar; Mai A Abd El Fattah; Walaa Wadie; Dalia M El-Tanbouly
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

5.  Cilostazol protects endothelial cells against lipopolysaccharide-induced apoptosis through ERK1/2- and P38 MAPK-dependent pathways.

Authors:  Jong-Hoon Lim; Jae-Suk Woo; Yung-Woo Shin
Journal:  Korean J Intern Med       Date:  2009-06-08       Impact factor: 3.165

6.  PTEN is destabilized by phosphorylation on Thr366.

Authors:  Helene Maccario; Nevin M Perera; Lindsay Davidson; C Peter Downes; Nick R Leslie
Journal:  Biochem J       Date:  2007-08-01       Impact factor: 3.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.